Bortezomib
Proteasome inhibitor / Potent and selective proteasome inhibitor (Ki=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC50=7 nM). Inhibits TNF synthesis and FGF-induced angiogenesis. Reversible. Cell permeable.
Biochemicals & reagents
179324-69-7
MG-341; PS-341; MLN341
1) Adams et al. (1999), Proteasome inhibitors: a novel class of potent and effective antitumor agents; Cancer Res., 59 2615 / 2) Williams et al. (2003), Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts; Mol. Cancer Ther., 2 835
-20°C
TARGET: Proteasome -- PATHWAY: Degradation; TNF; Proliferation; Cytokine -- RESEARCH AREA: Ubiquitin/Proteasome; Angiogenesis -- DISEASE AREA: Cancer